MD Anderson and Takeda Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform
The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited today announced an exclusive license agreement and research agreement to develop cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies, ‘armored’ with IL-15, for the treatment of B-cell malignancies and other cancers.
Under the agreement, Takeda will receive access to MD Anderson’s CAR NK platform and...
